HeartSciences Inc. (HSCS)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $3.09
- As of
Kresmion compiles this page from HSCS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
HeartSciences Inc. (HSCS): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full HSCS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for HSCS on one page. Preview it with sample data, then open it live with a free account.
Preview the HSCS dossierActive signals for HSCS
- mediumEARNINGS_MISS
Q1-2027: Missed consensus by 16.3%, EPS $-0.86 vs $-0.7395 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in HSCS
- mediumEARNINGS_MISS
Q4-2026: Missed consensus by 16.8%, EPS $-0.87 vs $-0.7446 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 18.1% - EPS $-1.88 vs $-2.295 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 18.5% - EPS $-1.58 vs $-1.938 estimate
FREE, NO ACCOUNT
Every signal on HSCS, as it fires
You are seeing 5 of 10 signals recorded on HSCS since 2026-05-30.
The five above landed across 4 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in HSCS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 42254E302 · 2026Q2 | $36K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, HSCS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
HSCS mentioned in Kresmion daily briefs
HSCS against its peers
HSCS's operating margin of -194787.4% ranks in the 2nd percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | HSCS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4319 USD | 4.5M USD | 2 | 21 |
| Gross margin | 59.1% | 53.7% | 52 | 21 |
| Operating margin | -194787.4% | -247.2% | 2 | 20 |
| Net margin | -211666.5% | -171.6% | 2 | 22 |
| Return on equity | -4044.0% | -137.2% | 2 | 22 |
| 1 year | -13.7% | -41.3% | 91 | 15 |
Peers (24): LFWD, GTHP, PMI, RDGL, MODD, PAVM, SINT, PLSM, BDMD, ALRTF, IRIX, PETV, FOFA, NSPR, CTSO, ITOC, NSYS, TNON, AEMD, ELUT, BMRA, CVRX, ARAY, QTI. Left out: NMTC (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (HSCS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow HSCS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to HSCS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.